positionForPages[221]={page:221,positions:[{w:"somatische SV's zouden, na validatie, kunnen worden gebruikt als patiënt-specifieke bio-",p:[0.147059,0.121273,0.882353,0.121273,0.882353,0.100900,0.147059,0.100900,0.007875,0.010843,0.017577,0.008811,0.006437,0.005615,0.007875,0.008765,0.011299,0.009039,0.003276,0.010112,0.015089,0.003196,0.007670,0.003276,0.008834,0.010820,0.011345,0.011322,0.009039,0.011756,0.004497,0.003276,0.011687,0.009291,0.003276,0.009838,0.009405,0.005250,0.005545,0.011573,0.008811,0.006437,0.005547,0.008743,0.004497,0.003276,0.010274,0.011413,0.011756,0.011596,0.009039,0.011756,0.003273,0.014518,0.010845,0.007442,0.011322,0.009039,0.011756,0.003276,0.009656,0.008902,0.010820,0.007964,0.011413,0.005752,0.010274,0.006437,0.003273,0.009405,0.005250,0.007670,0.003276,0.011368,0.008811,0.006437,0.005547,0.009039,0.011391,0.006437,0.007533,0.007510,0.011505,0.009108,0.008994,0.005615,0.005684,0.005613,0.008948,0.010274,0.009039,0.003276,0.010820,0.005547,0.011048,0.007533]},{w:"markers voor het volgen van kanker in circulerend tumor-DNA (ctDNA) door middel ",p:[0.147059,0.141852,0.886466,0.141852,0.886466,0.121479,0.147059,0.121479,0.017577,0.009085,0.007601,0.010272,0.009039,0.007624,0.007670,0.005182,0.009633,0.011276,0.010843,0.007807,0.005182,0.011299,0.009131,0.006437,0.005182,0.009633,0.010934,0.005250,0.009656,0.009039,0.011756,0.005182,0.009838,0.009085,0.011756,0.005182,0.010614,0.009085,0.011870,0.010274,0.009039,0.007807,0.005182,0.005615,0.011756,0.005182,0.008994,0.005615,0.007442,0.009108,0.011550,0.005182,0.009039,0.007442,0.009039,0.011596,0.011391,0.005182,0.006163,0.011413,0.017485,0.010843,0.007236,0.007533,0.015773,0.015408,0.014929,0.005182,0.006939,0.009108,0.006437,0.015773,0.015408,0.014929,0.006939,0.005182,0.011322,0.011276,0.010843,0.007807,0.005182,0.017645,0.005547,0.011322,0.011322,0.008948,0.005250,0.004109]},{w:"van ultragevoelige PCR-methoden. We hebben onze assay toegepast op tien ovarium- ",p:[0.147059,0.162431,0.886389,0.162431,0.886389,0.142058,0.147059,0.142058,0.009838,0.009085,0.011756,0.005798,0.011550,0.004908,0.006437,0.007898,0.009199,0.009656,0.009336,0.009633,0.011276,0.008948,0.005250,0.005615,0.009656,0.009039,0.005798,0.012167,0.014678,0.012349,0.007533,0.017483,0.009131,0.006620,0.011299,0.011276,0.011322,0.009039,0.011756,0.004497,0.005798,0.018649,0.009039,0.005798,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.005798,0.010843,0.011756,0.008834,0.009039,0.005798,0.009291,0.007533,0.007944,0.008925,0.009724,0.005798,0.006209,0.011276,0.009039,0.009656,0.009131,0.011368,0.009291,0.007510,0.006437,0.005798,0.010820,0.011276,0.005798,0.006437,0.005545,0.009039,0.011756,0.005798,0.010866,0.009838,0.009085,0.007807,0.005271,0.011413,0.017645,0.007533,0.004109]},{w:"en prostaatkankermonsters en hebben in slechts enkele dagen meerdere biomarkers per ",p:[0.147059,0.183009,0.886532,0.183009,0.886532,0.162636,0.147059,0.162636,0.009039,0.011756,0.004246,0.011071,0.007442,0.010957,0.007510,0.006551,0.009382,0.008811,0.006620,0.010614,0.009085,0.011870,0.010272,0.009039,0.007807,0.017485,0.010843,0.011619,0.007510,0.006209,0.009039,0.007624,0.007670,0.004246,0.009039,0.011756,0.004246,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.004246,0.005615,0.011756,0.004246,0.007556,0.005182,0.009108,0.008763,0.011096,0.006437,0.007670,0.004246,0.009039,0.011868,0.010272,0.008950,0.005182,0.009039,0.004246,0.011573,0.009199,0.009656,0.009039,0.011756,0.004246,0.017485,0.009108,0.009039,0.007442,0.011322,0.009039,0.007442,0.009039,0.004246,0.010820,0.005547,0.010843,0.017577,0.009085,0.007601,0.010272,0.009039,0.007624,0.007670,0.004246,0.011505,0.009039,0.007807,0.004109]},{w:"monster verkregen. We hebben in retrospect aangetoond dat longitudinale monitoring ",p:[0.147059,0.203588,0.886487,0.203588,0.886487,0.183215,0.147059,0.183215,0.017485,0.010843,0.011619,0.007510,0.006209,0.009039,0.007807,0.005182,0.009633,0.009039,0.007601,0.010706,0.007442,0.009039,0.009656,0.009039,0.011756,0.004497,0.005182,0.018649,0.009039,0.005182,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.005182,0.005615,0.011756,0.005182,0.007442,0.009131,0.006437,0.007442,0.010957,0.007510,0.011505,0.009108,0.009108,0.006437,0.005182,0.009384,0.009085,0.011459,0.009656,0.009131,0.006209,0.011276,0.010843,0.011596,0.011391,0.005182,0.011573,0.008809,0.006437,0.005182,0.005182,0.010843,0.011459,0.009861,0.005273,0.006163,0.011345,0.011391,0.005615,0.011687,0.009405,0.005182,0.009039,0.005182,0.017485,0.010843,0.011756,0.005273,0.006209,0.010843,0.007807,0.005615,0.011459,0.009861,0.004109]},{w:"van de kankerdynamiek mogelijk was met behulp van deze somatische SV-biomarkers. ",p:[0.147059,0.224167,0.886418,0.224167,0.886418,0.203794,0.147059,0.203794,0.009838,0.009085,0.011756,0.004931,0.011322,0.009039,0.004931,0.010614,0.009085,0.011870,0.010272,0.009039,0.007442,0.011322,0.009724,0.011687,0.009085,0.017645,0.005547,0.008948,0.010523,0.004931,0.017485,0.011048,0.009656,0.008948,0.005250,0.005273,0.005273,0.010523,0.004931,0.014723,0.009291,0.007670,0.004931,0.017485,0.009131,0.006437,0.004931,0.011254,0.008948,0.011094,0.011550,0.004908,0.011276,0.004931,0.009838,0.009085,0.011756,0.004931,0.011322,0.009336,0.008834,0.009039,0.004931,0.007875,0.010843,0.017577,0.008811,0.006437,0.005615,0.007875,0.008765,0.011299,0.009039,0.004931,0.010112,0.013308,0.007533,0.010820,0.005547,0.010843,0.017577,0.009085,0.007601,0.010272,0.009039,0.007624,0.007670,0.004497,0.004109]},{w:"Samenvattend maakte onze methode een snelle en kosteneffectieve identificatie mogelijk ",p:[0.147059,0.244745,0.886535,0.244745,0.886535,0.224373,0.147059,0.224373,0.010112,0.009085,0.017485,0.009039,0.011368,0.009838,0.008811,0.006163,0.006209,0.009039,0.011596,0.011391,0.003401,0.017577,0.009382,0.009405,0.010272,0.006209,0.009039,0.003401,0.010843,0.011756,0.008834,0.009039,0.003401,0.017485,0.009131,0.006620,0.011299,0.011276,0.011322,0.009039,0.003401,0.009108,0.009039,0.011756,0.003401,0.007601,0.011598,0.008948,0.005385,0.005184,0.009039,0.003401,0.009039,0.011756,0.003401,0.010272,0.010957,0.007510,0.006209,0.009039,0.011596,0.009039,0.005969,0.005787,0.009108,0.009108,0.006437,0.005547,0.009336,0.009633,0.009039,0.003401,0.005547,0.011322,0.009039,0.011391,0.006437,0.005615,0.005684,0.005615,0.009108,0.008811,0.006437,0.005547,0.009039,0.003401,0.017485,0.011048,0.009656,0.008948,0.005250,0.005273,0.005273,0.010523,0.004109]},{w:"van een reeks patiëntspecifieke SV's die kunnen worden gebruikt om ctDNA-dynamiek ",p:[0.147059,0.265324,0.886462,0.265324,0.886462,0.244951,0.147059,0.244951,0.009838,0.009085,0.011756,0.004485,0.009108,0.009039,0.011756,0.004485,0.007442,0.009108,0.008948,0.010523,0.007670,0.004485,0.011368,0.008811,0.006437,0.005547,0.009039,0.011391,0.006437,0.007510,0.011505,0.009108,0.008994,0.005615,0.005684,0.005613,0.008948,0.010272,0.009039,0.004485,0.010112,0.015089,0.003196,0.007670,0.004485,0.011391,0.005547,0.009039,0.004485,0.010272,0.011413,0.011756,0.011596,0.009039,0.011756,0.004485,0.014518,0.010843,0.007442,0.011324,0.009039,0.011756,0.004483,0.009658,0.008900,0.010820,0.007967,0.011413,0.005752,0.010272,0.006437,0.004485,0.010843,0.017645,0.004485,0.009108,0.006437,0.015773,0.015408,0.013605,0.007533,0.011322,0.009724,0.011687,0.009085,0.017645,0.005547,0.008948,0.010523,0.004109]},{w:"te bestuderen.",p:[0.147059,0.285903,0.264822,0.285903,0.264822,0.265530,0.147059,0.265530,0.006209,0.009039,0.004109,0.011254,0.009039,0.007510,0.006163,0.011345,0.011322,0.009039,0.007442,0.009039,0.011756,0.004497]},{w:"We hebben ook een assay ontwikkeld die gebruik maakt van op CRISPR-Cas9 geba-",p:[0.147059,0.327060,0.882353,0.327060,0.882353,0.306687,0.147059,0.306687,0.018649,0.009039,0.006688,0.011302,0.008902,0.010932,0.011254,0.009039,0.011756,0.006688,0.011276,0.010934,0.010523,0.006688,0.009108,0.009039,0.011756,0.006688,0.009291,0.007533,0.007944,0.008925,0.009724,0.006688,0.010843,0.011391,0.006437,0.014723,0.005752,0.010888,0.010272,0.008948,0.005182,0.011391,0.006688,0.011391,0.005547,0.009039,0.006688,0.009656,0.008902,0.010820,0.007967,0.011413,0.005752,0.010523,0.006688,0.017577,0.009382,0.009405,0.010272,0.006437,0.006688,0.009838,0.009087,0.011756,0.006688,0.010820,0.011276,0.006688,0.014678,0.013376,0.007259,0.009770,0.011664,0.012349,0.007533,0.014974,0.009291,0.007670,0.010432,0.006688,0.009656,0.008902,0.011117,0.009217,0.007533]},{w:"seerde verrijking van genomische targets bij pediatrische leukemieën uit de lymfoïde lijn. ",p:[0.147059,0.347639,0.886526,0.347639,0.886526,0.327266,0.147059,0.327266,0.007875,0.009108,0.009039,0.007442,0.011322,0.009039,0.003356,0.009633,0.009039,0.007807,0.007807,0.005273,0.005273,0.010706,0.005615,0.011459,0.009861,0.003356,0.009838,0.009085,0.011756,0.003356,0.009656,0.009039,0.011596,0.010843,0.017645,0.005615,0.007875,0.008765,0.011299,0.009039,0.003356,0.006551,0.009085,0.007624,0.009656,0.009131,0.006437,0.007670,0.003356,0.010818,0.005273,0.005273,0.003356,0.011505,0.009108,0.011391,0.005796,0.008811,0.006437,0.007807,0.005615,0.007875,0.008765,0.011299,0.009039,0.003356,0.005182,0.009131,0.011550,0.010272,0.009039,0.017645,0.005547,0.009108,0.009039,0.011756,0.003356,0.011413,0.005271,0.006437,0.003356,0.011322,0.009039,0.003356,0.005184,0.009724,0.017645,0.006026,0.010843,0.005547,0.011322,0.009039,0.003356,0.005250,0.005271,0.005273,0.011756,0.004497,0.004109]},{w:"In ",p:[0.147059,0.368218,0.169817,0.368218,0.169817,0.347845,0.147059,0.347845,0.006894,0.011756,0.004109]},{w:"hoofdstuk 6",p:[0.170908,0.368218,0.278078,0.368218,0.278078,0.347085,0.170908,0.347085,0.011779,0.011756,0.011322,0.006391,0.011801,0.008035,0.006825,0.012096,0.011162,0.005090,0.010911]},{w:" hebben we ons gericht op loci die herhaaldelijk betrokken zijn bij gen-",p:[0.278073,0.368218,0.882353,0.368218,0.882353,0.347845,0.278073,0.347845,0.005205,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.005205,0.014518,0.009039,0.005205,0.010843,0.011619,0.007670,0.005205,0.009656,0.009039,0.007807,0.005547,0.008763,0.011096,0.006437,0.005205,0.010820,0.011276,0.005205,0.005182,0.011276,0.008994,0.005615,0.005205,0.011391,0.005547,0.009039,0.005205,0.011299,0.009039,0.007601,0.011391,0.009382,0.009405,0.005182,0.011322,0.008948,0.005250,0.005273,0.005273,0.010523,0.005205,0.011251,0.009131,0.006437,0.007442,0.010934,0.010888,0.010272,0.009039,0.011756,0.005205,0.008834,0.005273,0.005273,0.011756,0.005205,0.010820,0.005273,0.005273,0.005205,0.009656,0.009039,0.011699,0.007533]},{w:"omische herschikkingen bij deze leukemieën, zoals de immunoglobuline (Ig) en T-cel-",p:[0.147059,0.388796,0.882353,0.388796,0.882353,0.368423,0.147059,0.368423,0.010843,0.017645,0.005615,0.007875,0.008765,0.011299,0.009039,0.005227,0.011299,0.009039,0.007624,0.007875,0.008765,0.011459,0.005752,0.010888,0.010706,0.005615,0.011459,0.009656,0.009039,0.011756,0.005227,0.010820,0.005273,0.005273,0.005227,0.011322,0.009336,0.008834,0.009039,0.005227,0.005182,0.009131,0.011550,0.010272,0.009039,0.017645,0.005547,0.009108,0.009039,0.011756,0.004497,0.005227,0.008834,0.011139,0.009405,0.005250,0.007670,0.005227,0.011322,0.009039,0.005227,0.005615,0.017645,0.017280,0.011413,0.011596,0.011048,0.009930,0.005182,0.010957,0.010797,0.011548,0.005250,0.005615,0.011596,0.009039,0.005227,0.006939,0.006483,0.009861,0.006939,0.005227,0.009039,0.011756,0.005227,0.011801,0.007533,0.008994,0.008948,0.005341,0.007533]},{w:"receptor (TCR) loci, en de KMT2A en SIL-TAL1 fusiegenen loci. Deze loci worden veel ",p:[0.147059,0.409375,0.886464,0.409375,0.886464,0.389002,0.147059,0.389002,0.007442,0.009108,0.008994,0.009131,0.011048,0.006209,0.010843,0.007807,0.004337,0.006825,0.013057,0.014678,0.013376,0.006939,0.004337,0.005182,0.011276,0.008994,0.005341,0.004497,0.004337,0.009039,0.011756,0.004337,0.011322,0.009039,0.004337,0.014541,0.019608,0.013354,0.010432,0.014929,0.004337,0.009039,0.011756,0.004337,0.009770,0.007259,0.011391,0.007533,0.011710,0.014929,0.011619,0.010432,0.004337,0.006366,0.011413,0.007601,0.005547,0.009039,0.009656,0.009039,0.011598,0.009039,0.011756,0.004337,0.005182,0.011276,0.008994,0.005341,0.004497,0.004337,0.016228,0.009336,0.008834,0.009039,0.004337,0.005182,0.011276,0.008994,0.005615,0.004337,0.014518,0.010843,0.007442,0.011324,0.009039,0.011756,0.004337,0.009633,0.009108,0.008948,0.005250,0.004109]},{w:"gebruikt voor op PCR gebaseerde tracering van minimale restziekte op basis van de pa-",p:[0.147059,0.429954,0.882353,0.429954,0.882353,0.409581,0.147059,0.409581,0.009656,0.008902,0.010820,0.007967,0.011413,0.005752,0.010272,0.006437,0.004497,0.009633,0.011276,0.010843,0.007807,0.004497,0.010820,0.011276,0.004497,0.012167,0.014678,0.013376,0.004497,0.009656,0.008902,0.011117,0.009291,0.007875,0.009108,0.009039,0.007442,0.011322,0.009039,0.004497,0.006437,0.007898,0.009291,0.008994,0.009039,0.007807,0.005615,0.011459,0.009861,0.004497,0.009838,0.009085,0.011756,0.004497,0.017645,0.005615,0.011756,0.005615,0.017574,0.009405,0.005182,0.009039,0.004497,0.007442,0.009039,0.007510,0.006506,0.008834,0.005545,0.008950,0.010272,0.006209,0.009039,0.004497,0.010820,0.011276,0.004497,0.011117,0.009291,0.007601,0.005615,0.007670,0.004497,0.009838,0.009087,0.011756,0.004497,0.011322,0.009039,0.004497,0.011368,0.009357,0.007533]},{w:"tiëntspecifieke herschikkingen. We hebben onze assay toegepast op tien acute lymfoïde ",p:[0.147059,0.450532,0.886416,0.450532,0.886416,0.430160,0.147059,0.430160,0.006437,0.005547,0.009039,0.011391,0.006437,0.007510,0.011505,0.009108,0.008994,0.005615,0.005684,0.005615,0.008948,0.010272,0.009039,0.004908,0.011299,0.009039,0.007624,0.007875,0.008765,0.011459,0.005752,0.010886,0.010706,0.005615,0.011459,0.009656,0.009039,0.011756,0.004497,0.004908,0.018649,0.009039,0.004908,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.004908,0.010843,0.011756,0.008834,0.009039,0.004908,0.009291,0.007533,0.007944,0.008925,0.009724,0.004908,0.006209,0.011276,0.009039,0.009656,0.009131,0.011368,0.009291,0.007510,0.006437,0.004908,0.010820,0.011276,0.004908,0.006437,0.005547,0.009039,0.011756,0.004908,0.009291,0.009106,0.011073,0.006209,0.009039,0.004908,0.005184,0.009724,0.017645,0.006024,0.010843,0.005547,0.011322,0.009039,0.004109]},{w:"leukemie monsters en hebben aangetoond dat we met succes de fusie, Ig en TCR loci ",p:[0.147059,0.471111,0.886423,0.471111,0.886423,0.450738,0.147059,0.450738,0.005182,0.009131,0.011550,0.010272,0.009039,0.017645,0.005547,0.009039,0.006072,0.017485,0.010843,0.011619,0.007512,0.006209,0.009039,0.007624,0.007670,0.006072,0.009039,0.011756,0.006072,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.006072,0.009384,0.009085,0.011459,0.009656,0.009131,0.006209,0.011276,0.010843,0.011596,0.011391,0.006072,0.011573,0.008811,0.006437,0.006072,0.014518,0.009039,0.006072,0.017485,0.009131,0.006437,0.006072,0.007510,0.011345,0.008994,0.008994,0.009039,0.007670,0.006072,0.011322,0.009039,0.006072,0.006369,0.011413,0.007601,0.005547,0.008743,0.004497,0.006072,0.006483,0.009861,0.006072,0.009039,0.011756,0.006072,0.013057,0.014678,0.013376,0.006072,0.005182,0.011276,0.008994,0.005615,0.004109]},{w:"hebben verrijkt. We hebben met succes bekende doelen van minimale restziekte bij deze ",p:[0.147059,0.491690,0.886555,0.491690,0.886555,0.471317,0.147059,0.471317,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.003995,0.009635,0.009039,0.007807,0.007807,0.005271,0.005273,0.010272,0.006437,0.004497,0.003995,0.018649,0.009039,0.003995,0.011299,0.008902,0.010934,0.011251,0.009039,0.011756,0.003995,0.017485,0.009131,0.006437,0.003995,0.007510,0.011345,0.008994,0.008994,0.009039,0.007670,0.003995,0.011254,0.008948,0.010272,0.009039,0.011596,0.011322,0.009039,0.003995,0.011324,0.011274,0.008948,0.005182,0.009039,0.011756,0.003995,0.009838,0.009085,0.011756,0.003995,0.017645,0.005615,0.011756,0.005615,0.017577,0.009405,0.005182,0.009039,0.003995,0.007442,0.009039,0.007512,0.006503,0.008834,0.005547,0.008948,0.010272,0.006211,0.009039,0.003995,0.010820,0.005273,0.005273,0.003995,0.011322,0.009336,0.008834,0.009039,0.004109]},{w:"patiënten gevalideerd binnen twee dagen na ontvangst van het monster en we hebben ",p:[0.147059,0.512269,0.886514,0.512269,0.886514,0.491896,0.147059,0.491896,0.011368,0.008811,0.006437,0.005547,0.009039,0.011391,0.006209,0.009039,0.011756,0.005684,0.009656,0.009336,0.009838,0.009405,0.005250,0.005547,0.011322,0.009108,0.009039,0.007442,0.011391,0.005684,0.010820,0.005615,0.011756,0.011596,0.009039,0.011756,0.005684,0.006437,0.014518,0.009108,0.009039,0.005684,0.011573,0.009199,0.009656,0.009039,0.011756,0.005684,0.011690,0.009291,0.005684,0.010843,0.011391,0.006437,0.009838,0.009085,0.011459,0.009724,0.007510,0.006437,0.005684,0.009838,0.009087,0.011756,0.005684,0.011299,0.009131,0.006437,0.005684,0.017485,0.010843,0.011619,0.007510,0.006209,0.009039,0.007807,0.005684,0.009039,0.011756,0.005684,0.014518,0.009039,0.005684,0.011299,0.008902,0.010934,0.011254,0.009039,0.011756,0.004109]},{w:"een aanvullende reeks patiëntspecifieke herschikkingen geïdentificeerd. Onze aanpak ",p:[0.147059,0.532847,0.886441,0.532847,0.886441,0.512474,0.147059,0.512474,0.009108,0.009039,0.011756,0.007145,0.009382,0.009085,0.011368,0.009838,0.011550,0.005387,0.005182,0.009039,0.011596,0.011322,0.009039,0.007145,0.007442,0.009108,0.008948,0.010523,0.007670,0.007145,0.011368,0.008811,0.006437,0.005547,0.009039,0.011391,0.006437,0.007510,0.011505,0.009108,0.008994,0.005615,0.005684,0.005615,0.008948,0.010272,0.009039,0.007145,0.011302,0.009039,0.007624,0.007873,0.008765,0.011459,0.005752,0.010888,0.010706,0.005615,0.011459,0.009656,0.009039,0.011756,0.007145,0.009656,0.009039,0.005547,0.011322,0.009039,0.011391,0.006437,0.005615,0.005684,0.005615,0.008994,0.009108,0.009039,0.007442,0.011117,0.004497,0.007145,0.016298,0.011756,0.008834,0.009039,0.007145,0.009382,0.009085,0.011391,0.011368,0.009405,0.010523,0.004109]},{w:"vormt een geschikt alternatief voor de huidige meerstaps biomarker-identificatie assays ",p:[0.147059,0.553426,0.886482,0.553426,0.886482,0.533053,0.147059,0.533053,0.009633,0.010843,0.007807,0.017280,0.006437,0.004908,0.009108,0.009039,0.011756,0.004908,0.009656,0.009039,0.007873,0.008768,0.011459,0.005750,0.010272,0.006437,0.004908,0.009405,0.004908,0.006209,0.009039,0.007807,0.011687,0.008811,0.006437,0.005547,0.009039,0.006209,0.004908,0.009633,0.011276,0.010843,0.007807,0.004908,0.011322,0.009039,0.004908,0.011094,0.011413,0.005547,0.011391,0.005615,0.009653,0.009039,0.004908,0.017485,0.009108,0.009039,0.007624,0.007510,0.006551,0.008811,0.011185,0.007670,0.004908,0.010820,0.005547,0.010843,0.017577,0.009085,0.007601,0.010272,0.009039,0.007236,0.007533,0.005547,0.011322,0.009039,0.011391,0.006437,0.005615,0.005684,0.005615,0.009108,0.008811,0.006437,0.005547,0.009039,0.004908,0.009291,0.007533,0.007941,0.008928,0.009724,0.007670,0.004109]},{w:"bij lymfoïde leukemie, met verhoogde snelheid en detectiegevoeligheid.",p:[0.147059,0.574005,0.745735,0.574005,0.745735,0.553632,0.147059,0.553632,0.010820,0.005273,0.005273,0.004109,0.005182,0.009724,0.017645,0.006026,0.010843,0.005547,0.011322,0.009039,0.004109,0.005182,0.009128,0.011550,0.010274,0.009039,0.017645,0.005545,0.008743,0.004497,0.004109,0.017485,0.009131,0.006437,0.004109,0.009633,0.009039,0.007601,0.011302,0.011274,0.011048,0.009656,0.011322,0.009039,0.004109,0.007601,0.011598,0.008946,0.005387,0.011302,0.009039,0.005545,0.011391,0.004109,0.009039,0.011756,0.004109,0.011322,0.009131,0.006209,0.009108,0.009108,0.006437,0.005547,0.009039,0.009656,0.009336,0.009633,0.011276,0.008948,0.005250,0.005615,0.009930,0.011299,0.009039,0.005547,0.011117,0.004497]},{w:"Ten slotte heb ik in ",p:[0.147059,0.615162,0.311754,0.615162,0.311754,0.594789,0.147059,0.594789,0.010866,0.009039,0.011756,0.004771,0.007556,0.005182,0.010820,0.006163,0.006209,0.009039,0.004771,0.011299,0.008902,0.011025,0.004771,0.005752,0.010523,0.004771,0.005615,0.011756,0.004109]},{w:"hoofdstuk 7",p:[0.312462,0.615162,0.419221,0.615162,0.419221,0.594029,0.312462,0.594029,0.011779,0.011756,0.011322,0.006391,0.011801,0.008035,0.006825,0.012096,0.011162,0.004679,0.010911]},{w:" de technologische vooruitgang die in de vorige hoofd-",p:[0.419216,0.615162,0.882353,0.615162,0.882353,0.594789,0.419216,0.594789,0.004771,0.011322,0.009039,0.004771,0.006209,0.009108,0.008765,0.011459,0.011596,0.010934,0.005182,0.011048,0.009861,0.005615,0.007875,0.008765,0.011299,0.009039,0.004771,0.009633,0.011276,0.010843,0.007967,0.011413,0.005273,0.006437,0.009861,0.009085,0.011459,0.009861,0.004771,0.011391,0.005547,0.009039,0.004771,0.005615,0.011756,0.004771,0.011322,0.009039,0.004771,0.009635,0.010843,0.007807,0.005615,0.009656,0.009039,0.004771,0.011299,0.011276,0.010843,0.006026,0.011461,0.007533]},{w:"stukken zijn gepresenteerd bediscussieerd. Ik heb de voordelen van PDO-technologie ",p:[0.147059,0.635741,0.886507,0.635741,0.886507,0.615368,0.147059,0.615368,0.007510,0.006163,0.011550,0.010888,0.010272,0.009039,0.011756,0.006140,0.008834,0.005273,0.005273,0.011756,0.006140,0.009656,0.009131,0.011071,0.007442,0.009039,0.007875,0.009039,0.011391,0.006209,0.009108,0.009039,0.007442,0.011391,0.006140,0.011254,0.009108,0.011391,0.005615,0.007873,0.009108,0.011413,0.007533,0.007601,0.005547,0.009108,0.009039,0.007442,0.011117,0.004497,0.006140,0.007190,0.010523,0.006140,0.011299,0.008902,0.011025,0.006140,0.011322,0.009039,0.006140,0.009633,0.011276,0.010843,0.007442,0.011322,0.008948,0.005182,0.009039,0.011756,0.006140,0.009838,0.009085,0.011756,0.006140,0.011664,0.016504,0.016412,0.007533,0.006209,0.009106,0.008768,0.011459,0.011598,0.010934,0.005182,0.011048,0.009861,0.005545,0.009039,0.004109]},{w:"voor eierstokkankeronderzoek uitgelegd, maar ook de uitdagingen voor de verdere im-",p:[0.147059,0.656319,0.882353,0.656319,0.882353,0.635947,0.147059,0.635947,0.009633,0.011276,0.010843,0.007807,0.004748,0.009039,0.005547,0.009039,0.007624,0.007510,0.006209,0.010934,0.010888,0.010614,0.009085,0.011870,0.010272,0.009039,0.007442,0.010843,0.011596,0.011322,0.009039,0.007807,0.008834,0.011276,0.008948,0.010523,0.004748,0.011413,0.005273,0.006437,0.009656,0.008948,0.005182,0.009039,0.009656,0.011117,0.004497,0.004748,0.017577,0.009382,0.009085,0.007807,0.004748,0.011274,0.010936,0.010523,0.004748,0.011320,0.009039,0.004748,0.011413,0.005273,0.006209,0.011573,0.009199,0.009861,0.005615,0.011459,0.009656,0.009039,0.011756,0.004748,0.009633,0.011276,0.010843,0.007807,0.004748,0.011322,0.009039,0.004748,0.009633,0.009039,0.007442,0.011322,0.009039,0.007442,0.009039,0.004748,0.005615,0.017714,0.007533]},{w:"plementatie in de klinische zorg. Daarnaast besprak ik de bestaande uitdagingen om-",p:[0.147059,0.676898,0.882353,0.676898,0.882353,0.656525,0.147059,0.656525,0.011162,0.005182,0.009039,0.017485,0.009039,0.011391,0.006551,0.008811,0.006437,0.005547,0.009039,0.006209,0.005615,0.011756,0.006209,0.011322,0.009039,0.006209,0.010888,0.005250,0.005615,0.011756,0.005615,0.007873,0.008765,0.011299,0.009039,0.006209,0.008834,0.010843,0.007624,0.009679,0.004497,0.006209,0.016207,0.009382,0.009085,0.007807,0.011687,0.009382,0.009291,0.007510,0.006437,0.006209,0.011254,0.009039,0.007510,0.011071,0.007898,0.009405,0.010523,0.006209,0.005752,0.010523,0.006209,0.011322,0.009039,0.006209,0.011254,0.009039,0.007510,0.006551,0.009380,0.009085,0.011598,0.011322,0.009039,0.006209,0.011413,0.005273,0.006209,0.011573,0.009199,0.009861,0.005615,0.011459,0.009658,0.009039,0.011756,0.006209,0.010840,0.017668,0.007533]},{w:"trent somatische SV’s en stel ik verschillende oplossingen voor om de kennis van de rol ",p:[0.147059,0.697477,0.886507,0.697477,0.886507,0.677104,0.147059,0.677104,0.006437,0.007442,0.009039,0.011391,0.006437,0.004953,0.007873,0.010843,0.017577,0.008811,0.006437,0.005615,0.007875,0.008765,0.011299,0.009039,0.004953,0.010112,0.014929,0.001735,0.007670,0.004953,0.009039,0.011756,0.004953,0.007510,0.006209,0.008948,0.005250,0.004953,0.005752,0.010523,0.004953,0.009633,0.009039,0.007624,0.007873,0.008768,0.011459,0.005750,0.005387,0.005182,0.009039,0.011596,0.011322,0.009039,0.004953,0.010820,0.011162,0.005182,0.010957,0.007533,0.007601,0.005615,0.011459,0.009656,0.009039,0.011756,0.004953,0.009635,0.011274,0.010845,0.007807,0.004953,0.010843,0.017645,0.004953,0.011322,0.009039,0.004953,0.010272,0.009039,0.011756,0.011756,0.005615,0.007670,0.004953,0.009838,0.009085,0.011756,0.004953,0.011322,0.009039,0.004953,0.007442,0.010934,0.005250,0.004109]},{w:"van somatische SV's bij kanker en implementatie van Nanopore sequencing technologie ",p:[0.147059,0.718056,0.886553,0.718056,0.886553,0.697683,0.147059,0.697683,0.009838,0.009085,0.011756,0.004018,0.007875,0.010843,0.017577,0.008811,0.006437,0.005615,0.007875,0.008765,0.011299,0.009039,0.004018,0.010112,0.015089,0.003196,0.007670,0.004018,0.010820,0.005271,0.005273,0.004018,0.010614,0.009085,0.011870,0.010272,0.009039,0.007807,0.004018,0.009039,0.011756,0.004018,0.005615,0.017280,0.011162,0.005182,0.009039,0.017485,0.009039,0.011391,0.006551,0.008811,0.006437,0.005547,0.009039,0.004018,0.009838,0.009085,0.011756,0.004018,0.015545,0.009085,0.011596,0.010820,0.011505,0.010843,0.007442,0.009039,0.004018,0.007875,0.009108,0.010706,0.011345,0.009039,0.011596,0.008994,0.005615,0.011459,0.009861,0.004018,0.006209,0.009108,0.008765,0.011459,0.011596,0.010934,0.005182,0.011048,0.009861,0.005547,0.009039,0.004109]},{w:"te vergroten. Concluderend stelt dit proefschrift verschillende kanker genomics geba-",p:[0.147059,0.738634,0.882353,0.738634,0.882353,0.718261,0.147059,0.718261,0.006209,0.009039,0.006446,0.009635,0.009039,0.007624,0.009861,0.007442,0.010818,0.006211,0.009039,0.011756,0.004497,0.006446,0.014997,0.010843,0.011596,0.008765,0.004908,0.011345,0.011322,0.009039,0.007442,0.009039,0.011596,0.011391,0.006446,0.007512,0.006209,0.008946,0.004910,0.006437,0.006446,0.011391,0.005273,0.006437,0.006446,0.011071,0.007442,0.011276,0.009039,0.006072,0.007875,0.008765,0.011459,0.007807,0.005615,0.006197,0.006197,0.006446,0.009633,0.009039,0.007624,0.007875,0.008765,0.011459,0.005752,0.005387,0.005182,0.009039,0.011596,0.011322,0.009039,0.006446,0.010614,0.009087,0.011868,0.010272,0.009039,0.007807,0.006449,0.009656,0.009039,0.011596,0.010843,0.017645,0.005547,0.008994,0.007670,0.006446,0.009656,0.008902,0.011117,0.009291,0.007533]},{w:"seerde technologische mogelijkheden voor om kankeronderzoek vooruit te helpen en ",p:[0.147059,0.759213,0.886462,0.759213,0.886462,0.738840,0.147059,0.738840,0.007875,0.009108,0.009039,0.007442,0.011322,0.009039,0.006163,0.006209,0.009108,0.008765,0.011459,0.011596,0.010934,0.005182,0.011048,0.009861,0.005615,0.007873,0.008768,0.011299,0.009039,0.006163,0.017485,0.011048,0.009656,0.008948,0.005250,0.005273,0.005273,0.010886,0.011299,0.009108,0.011322,0.009039,0.011756,0.006163,0.009633,0.011276,0.010843,0.007807,0.006163,0.010843,0.017645,0.006163,0.010614,0.009087,0.011868,0.010272,0.009039,0.007442,0.010845,0.011596,0.011322,0.009039,0.007807,0.008834,0.011274,0.008948,0.010523,0.006163,0.009635,0.011274,0.010845,0.007964,0.011413,0.005273,0.006437,0.006163,0.006209,0.009039,0.006163,0.011299,0.008948,0.004908,0.011505,0.009039,0.011756,0.006163,0.009039,0.011756,0.004109]},{w:"gepersonaliseerde diagnostische assays te ontwikkelen om het ziektebeloop van patiënt-",p:[0.147059,0.779792,0.882353,0.779792,0.882353,0.759419,0.147059,0.759419,0.009656,0.009131,0.011505,0.009039,0.007624,0.007875,0.010843,0.011687,0.009405,0.005250,0.005615,0.007873,0.009108,0.009039,0.007442,0.011322,0.009039,0.004097,0.011391,0.005798,0.009197,0.009861,0.011598,0.010957,0.007510,0.006437,0.005615,0.007873,0.008765,0.011299,0.009039,0.004097,0.009291,0.007533,0.007944,0.008925,0.009724,0.007670,0.004095,0.006209,0.009039,0.004097,0.010843,0.011391,0.006437,0.014723,0.005752,0.010888,0.010272,0.008948,0.005182,0.009039,0.011756,0.004095,0.010843,0.017645,0.004097,0.011299,0.009131,0.006437,0.004095,0.008834,0.005547,0.008948,0.010272,0.006209,0.008902,0.011254,0.008948,0.005182,0.011276,0.010820,0.011276,0.004095,0.009838,0.009087,0.011756,0.004095,0.011368,0.008811,0.006437,0.005547,0.009039,0.011391,0.006437,0.007533]},{w:"en positief te beïnvloeden.",p:[0.147059,0.800370,0.367358,0.800370,0.367358,0.779998,0.147059,0.779998,0.009039,0.011756,0.004109,0.011505,0.010957,0.007601,0.005273,0.006437,0.005547,0.009039,0.006209,0.004109,0.006207,0.009039,0.004109,0.011254,0.009039,0.005615,0.011368,0.009907,0.005182,0.011276,0.009108,0.011322,0.009039,0.011756,0.004497]},{w:"213",p:[0.890196,0.957873,0.914035,0.957873,0.914035,0.938882,0.890196,0.938882,0.007923,0.007325,0.008591]},{w:"SAMENVATTING",p:[0.772374,0.066557,0.882354,0.066557,0.882354,0.045634,0.772374,0.045634,0.009405,0.009679,0.013582,0.008537,0.010706,0.008514,0.008674,0.007807,0.007807,0.004291,0.010706,0.010272]}]};